Key result
Nesiritide infusion for ≥24 hours was significantly associated with worsening renal function compared to <24 hours (26.1% vs 2.6%; adjusted OR 10.46; 95% CI 1.26-86.72; P=0.03).
Why the study?
Does nesiritide infusion for 24 hours or more increase the risk of worsening renal function in patients with acutely decompensated heart failure compared to infusion for less than 24 hours?
Population
84 hospitalized patients with acutely decompensated heart failure
Comparison
Nesiritide infusion for 24 hours or more vs Nesiritide infusion for less than 24 hours
Design
Cohort
Follow-up
during infusion
Authors
Loading...
May warrant shorter nesiritide infusions in acute HF; leaves open optimal duration in randomized trials.
Cohort (n=84)
Does nesiritide infusion for 24 hours or more increase the risk of worsening renal function in patients with acutely decompensated heart failure compared to infusion for less than 24 hours?
Odds Ratio: 10.46 (95% CI 1.26–86.72)
Absolute Event Rate: 26.1% vs 2.6%
p-value: p=0.03
In patients with acutely decompensated heart failure, nesiritide infusion for 24 hours or more is associated with a significantly higher risk of worsening renal function compared to shorter infusion durations.
Chow et al. (2007) conducted a cohort in acutely decompensated heart failure (n=84). Nesiritide infusion duration ≥ 24 hours vs. Nesiritide infusion duration < 24 hours was evaluated on Worsening renal function (increase in serum creatinine ≥ 0.5 mg/dL from baseline) (OR 10.46, 95% CI 1.26 to 86.72, p=0.03). Nesiritide infusion for ≥24 hours was significantly associated with worsening renal function compared to <24 hours (26.1% vs 2.6%; adjusted OR 10.46; 95% CI 1.26-86.72; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: